The scientist’s investigation covers issues in Stereochemistry, Factor Xa Inhibitor, Protease, Copper and Enzyme. His biological study spans a wide range of topics, including Proteases, Group, Salt, Structure–activity relationship and Enzyme inhibitor. His Factor Xa Inhibitor research incorporates elements of Pyrazole, Thrombin and Benzamidine.
His work carried out in the field of Pyrazole brings together such families of science as Bicyclic molecule and Carboxamide. His Copper study combines topics in areas such as Polymer chemistry and Coupling reaction. His research investigates the connection between Enzyme and topics such as Anticoagulant Agent that intersect with problems in Discovery and development of direct thrombin inhibitors.
Patrick Y.S. Lam mainly focuses on Stereochemistry, Factor Xa Inhibitor, Protease, Pharmacology and Enzyme inhibitor. His Stereochemistry study combines topics from a wide range of disciplines, such as Structure–activity relationship, Chemical synthesis and Enzyme. His Factor Xa Inhibitor research is multidisciplinary, incorporating perspectives in Lactam, Salt, Guanidine and Carboxamide.
His Protease research is multidisciplinary, incorporating elements of Urea and Virus. His work on Bioavailability as part of general Pharmacology study is frequently linked to Fibrinolytic agent, bridging the gap between disciplines. His Enzyme inhibitor research includes elements of Benzamidine, Amidine, Molecular model and Thrombin.
Pharmacology, Stereochemistry, Antithrombotic, Combinatorial chemistry and Bioavailability are his primary areas of study. His work on Pharmacokinetics as part of general Pharmacology research is frequently linked to In vivo, thereby connecting diverse disciplines of science. In his research, he undertakes multidisciplinary study on Stereochemistry and P2y1 receptor.
His Antithrombotic research is multidisciplinary, relying on both P2Y12, Antagonist, Coagulation, Thrombus and Drug discovery. His Combinatorial chemistry study integrates concerns from other disciplines, such as Factor XIa, Structure–activity relationship, Imidazole and Enzyme. Many of his studies on Bioavailability involve topics that are commonly interrelated, such as Factor Xa Inhibitor.
His primary areas of study are Pharmacology, Stereochemistry, Antithrombotic, Factor XIa and Combinatorial chemistry. His studies in Pharmacology integrate themes in fields like Clotting time and Potency. Patrick Y.S. Lam combines subjects such as Selectivity and Bioavailability with his study of Stereochemistry.
His study focuses on the intersection of Antithrombotic and fields such as Antagonist with connections in the field of Piperidine, Indoline, Lead compound, Urea and Platelet. His Combinatorial chemistry study incorporates themes from Carbon, Chemical synthesis, Chemical coupling and Reaction mechanism. His work deals with themes such as Chan-Lam coupling, Coupling reaction and Copper, which intersect with Chemical coupling.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
New aryl/heteroaryl CN bond cross-coupling reactions via arylboronic acid/cupric acetate arylation
Patrick Y.S Lam;Charles G Clark;Simon Saubern;Jessica Adams.
Tetrahedron Letters (1998)
Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors
PY Lam;PK Jadhav;CJ Eyermann;CN Hodge.
Science (1994)
Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa.
Donald J.P. Pinto;Michael J. Orwat;Stephanie Koch;Karen A. Rossi.
Journal of Medicinal Chemistry (2007)
Copper-Promoted Carbon-HeteroatomBond Cross-Coupling with Boronic Acids and Derivatives
Jennifer X. Qiao;Patrick Y. S. Lam.
Synthesis (2011)
Copper-catalyzed general CN and CO bond cross-coupling with arylboronic acid
Patrick Y.S Lam;Guillaume Vincent;Charles G Clark;Sophie Deudon.
Tetrahedron Letters (2001)
Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.
P. C. Wong;E. J. Crain;B. Xin;R. R. Wexler.
Journal of Thrombosis and Haemostasis (2008)
Flexibility and function in HIV-1 protease
Linda K. Nicholson;Toshimasa Yamazaki;Dennis A. Torchia;Stephan Grzesiek.
Nature Structural & Molecular Biology (1995)
Lactam-containing compounds and derivatives thereof as factor xa inhibitors
Donald J.P. Pinto;Mimi L. Quan;Michael J. Orwat;Yun-Long Li.
(2002)
Copper-Promoted C−N Bond Cross-Coupling with Hypervalent Aryl Siloxanes and Room-Temperature N-Arylation with Aryl Iodide
Patrick Y. S. Lam;Sophie Deudon;Kristin M. Averill;Renhua Li.
Journal of the American Chemical Society (2000)
Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.
Donald J. P. Pinto;Michael J. Orwat;Shuaige Wang;John M. Fevig.
Journal of Medicinal Chemistry (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of California, Los Angeles
National Institutes of Health
National Institutes of Health
National Institutes of Health
Scripps (United States)
Télécom ParisTech
Lawrence Berkeley National Laboratory
Mayo Clinic
Huazhong University of Science and Technology
Kyoto University
University of Florida
National Autonomous University of Mexico
University of Cape Town
Helmholtz Centre for Environmental Research
Joint Research Centre
Charité - University Medicine Berlin
University of British Columbia
University of Cape Town
Philipp University of Marburg
Lingnan University
University of Chicago